The combined result is improved glucose control and reduced calorie intake, resulting in weight loss
Based on Phase 2 trial data (Jastreboff et al., NEJM , 2023), the most commonly reported adverse effects of retatrutide include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (most frequent, particularly during dose escalation) Injection site reactions: Redness, bruising, or mild discomfort Decreased appetite: Generally considered a therapeutic effect but can contribute to nutritional deficiency if severe Increased heart rate: Observed with glucagon receptor agonism
Research overview Other vial-size protocols Related protocols and comparisons CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack Dosage Protocol CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack Dosage Protocol AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) Dosage Protocol
[12] The oral upper intake levels established for dietary copper do not translate directly to a copper-carrying peptide delivered subcutaneously, which bypasses the intestinal regulation of copper absorption entirely one more reason the systemic dosing of GHK-Cu is genuinely uncharacterized in humans
GLP-1s aren't a standalone prescription
PURE FORMULATION QUALITY YOU CAN TRUST Made without additives, artificial colours, or common allergens like wheat, dairy, yeast, or gluten